Clinical Trial Network for Pivotal FDA Study Complete
| Stock | Blinklab Ltd (BB1.ASX) |
|---|---|
| Release Time | 16 Mar 2026, 9:44 a.m. |
| Price Sensitive | Yes |
BlinkLab Completes Clinical Trial Network for Pivotal FDA Study
- Final Clinical Site Onboarded: University of Arkansas joins BlinkLab's pivotal FDA 510(k) clinical trial
- Onboarding of Clinical Sites Now Complete: 10 leading U.S. clinical sites will participate in the pivotal study
- U.S. Pilot Data Strengthens and De-Risks Pivotal Study: BlinkLab Dx 1 demonstrated high diagnostic accuracy
BlinkLab Limited (ASX:BB1) has announced the completion of onboarding the clinical site network for its upcoming pivotal FDA 510(k) clinical trial of its BlinkLab Dx 1 smartphone-based diagnostic aid for detecting autism. The final site to be added is the University of Arkansas, a globally recognised research university. This brings the total number of leading U.S. clinical sites participating in the pivotal study to 10, including institutions such as Cincinnati Children's Hospital, Seattle Children's Hospital, and the University of Pennsylvania. The pivotal study will validate the usability and diagnostic accuracy of BlinkLab Dx 1 and is set to commence in Q1 2026, enrolling a minimum of 528 children. The network of clinical sites strengthens the study design and represents a geographically and demographically diverse population. This follows BlinkLab's recent U.S. pilot study of 485 children, where its flagship technology demonstrated 83.7% sensitivity and 84.7% specificity for autism, significantly exceeding the performance thresholds agreed with the FDA. By anchoring the pivotal trial in this elite network of clinical sites, BlinkLab is not only generating high-quality evidence for regulatory clearance but also building deep relationships with key opinion leaders and future implementation partners, which are expected to play a critical role in informing real-world clinical workflows, supporting guideline and payer engagement, and accelerating adoption upon FDA clearance.
A successful pivotal study and subsequent FDA 510(k) clearance would position the BlinkLab Dx 1 technology as a first-of-its-kind AI-powered diagnostic aid that can be deployed at scale, ultimately bringing earlier and more objective autism assessments into clinics and communities to help address long waitlists, regional inequities, and delayed care and support.